Title |
Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale
|
---|---|
Published in |
Trials, January 2011
|
DOI | 10.1186/1745-6215-12-20 |
Pubmed ID | |
Authors |
A Marjolein Schrijver, Michel MPJ Reijnen, Jacques A van Oostayen, Rudolf PJ Tutein Nolthenius, Pieter HM van der Valk, Arjan WJ Hoksbergen, Rutger J Lely, Bram Fioole, Dammis Vroegindeweij, Marc van Leersum, Jean-Paul PM de Vries |
Abstract |
The use of thrombolytic therapy in the treatment of thrombosed infrainguinal native arteries and bypass grafts has increased over the years. Main limitation of this treatment modality, however, is the occurrence of bleeding complications. Low intensity ultrasound (US) has been shown to accelerate enzymatic thrombolysis, thereby reducing therapy time. So far, no randomized trials have investigated the application of US-accelerated thrombolysis in the treatment of thrombosed infra-inguinal native arteries or bypass grafts. The DUET study (Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thrombo-embolic infrainguinal disease) is designed to assess whether US-accelerated thrombolysis will reduce therapy time significantly compared with standard catheter-directed thrombolysis. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 3% |
United States | 1 | 3% |
Netherlands | 1 | 3% |
Unknown | 31 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 15% |
Student > Ph. D. Student | 5 | 15% |
Student > Master | 4 | 12% |
Librarian | 3 | 9% |
Other | 2 | 6% |
Other | 5 | 15% |
Unknown | 10 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 50% |
Agricultural and Biological Sciences | 2 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Psychology | 1 | 3% |
Engineering | 1 | 3% |
Other | 0 | 0% |
Unknown | 12 | 35% |